[25-NSE] IGM Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

IGM Biosciences, Inc. filed a Form 25 notifying the removal of its common stock from listing and/or registration on the Nasdaq Stock Market LLC. The filing includes statements that Nasdaq has complied with 17 CFR 240.12d2-2(b) and that the issuer has complied with 17 CFR 240.12d2-2(c) governing voluntary withdrawal. The document is signed by Tara Petta, AVP and dated 2025-08-14. The filing does not disclose an effective date for removal, the specific rule provision selected on the form, or the underlying reasons for the removal.

Insights

Securities Analyst

TL;DR: Nasdaq filed to remove IGMS common stock; filing shows procedural compliance but provides no timing or rationale.

The Form 25 formally notifies market participants that IGM Biosciences' common stock is to be removed from Nasdaq listing and/or registration. The document explicitly cites compliance with 17 CFR 240.12d2-2(b) by the Exchange and 17 CFR 240.12d2-2(c) by the issuer, and it is signed and dated 2025-08-14 by an AVP of Nasdaq. Material investor information typically tied to such a filing—an effective removal date, reason for delisting or withdrawal, and any transition arrangements for trading—is absent from the filing. The lack of those details increases uncertainty for holders about timing and trading implications.

Corporate Governance Expert

TL;DR: Form 25 signals a removal/withdrawal event with exchange and issuer compliance statements; the filing omits explanatory details or next steps.

The submission meets procedural requirements by including compliance statements under 17 CFR 240.12d2-2(b) and 240.12d2-2(c) and is executed by Nasdaq personnel. From a governance and disclosure standpoint, the filing is limited to the notification itself and does not contain the issuer's explanation, board actions, shareholder communications, or effective-date information. For stakeholders, this means the document confirms an imminent change in listing status but does not provide governance context or operational details that would clarify implications for shareholders.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-39045

Issuer:	IGM Biosciences, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	325 E Middlefield Road
	Mountain View	CALIFORNIA	94043
Telephone number:					650-965-7873

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-08-14	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What action did Nasdaq take regarding IGM Biosciences (IGMS)?

Nasdaq filed a Form 25 notifying the removal of IGM Biosciences' common stock from listing and/or registration on the Nasdaq Stock Market LLC.

When was the Form 25 for IGMS signed and by whom?

The Form 25 is signed by Tara Petta, AVP and dated 2025-08-14.

Which class of securities is affected for IGM Biosciences (IGMS)?

The filing specifies that the affected class is Common Stock.

Does the filing state whether the withdrawal is voluntary or initiated by the exchange?

The document includes statements referencing both 17 CFR 240.12d2-2(b) (exchange compliance) and 17 CFR 240.12d2-2(c) (issuer compliance for voluntary withdrawal); the form does not indicate which specific rule provision was selected.

Does the Form 25 disclose the effective date or reasons for removal?

No. The filing does not disclose an effective date for removal nor provide reasons or additional explanatory details.